Meeting
2022 ASCO Annual Meeting
Pan-cancer landscape of CD274 (PD-L1) and PDCD1LG2 (PD-L2) structural variations.
Authors
Emily Louise Hoskins
Ohio State University, Columbus, OH
Emily Louise Hoskins , Eric Samarodnitsky , Michele Wing , Julie Reeser , Julia Hopkins , Karthikeyan Murugesan , Zheng Kuang , Leah Stein , Zachary Risch , Raven Vella , Serifat Abedola , Lianbo Yu , Anoosha Paruchuri , Richard S.P. Huang , Lee A. Albacker , Sameek Roychowdhury
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3133)
DOI
10.1200/JCO.2022.40.16_suppl.3133
Abstract #
3133
Poster Bd #
125
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer (LC): implications for immunotherapy.
First Author: David James Pinato
Poster
2014 ASCO Annual Meeting
Programmed death 1 (PD-1) lymphocytes and ligand (PD-L1) in colorectal cancer and their relationship to microsatellite instability status.
First Author: Zoran Gatalica
Poster
2024 ASCO Genitourinary Cancers Symposium
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
First Author: Mathilde Cancel
Poster
2022 ASCO Annual Meeting
Immuno-multiple reaction monitoring (iMRM) for quantitation of PD-L1 and PD-1-signaling proteins in non-small cell lung carcinoma (NSCLC).
First Author: Vincent Lacasse